<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146626</url>
  </required_header>
  <id_info>
    <org_study_id>HCV +Vitamin D</org_study_id>
    <nct_id>NCT01146626</nct_id>
  </id_info>
  <brief_title>Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?</brief_title>
  <official_title>Does Vitamin D Supplement Improve SVR in Chronic Hepatitis C (Genotype 2,3) in na誰ve Patients Treated With Peginterferon Alpha and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy
      obtaining sustained virologic response (SVR) in 80% of na誰ve patients with genotype 2,3.
      Studies rarely address the issues of improving host factors. The current study examines

        1. whether adding vitamin D, a potent immunomodulator, could improve viral response and
           shorten treatment duration (from 24 weeks to 12 weeks)

        2. whether Vitamin D levels predictes negative treatment outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy
      obtaining sustained virologic response (SVR) in 80% of na誰ve patients with genotype 2,3.
      Studies rarely address the issues of improving host factors. The current study examines
      whether adding vitamin D, a potent immunomodulator, could improve viral respons.The working
      hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for na誰ve, genotype 2,3
      patients with chronic HCV infection significantly improves RVR, EVR, and SVR
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR rate</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate the response rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peg+ Vitamin D+ Ribavirine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peg+ Vitamin D+ Ribavirine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peg+ Ribavirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg+ Ribavirine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg+ Vitamin D+ Ribavirine</intervention_name>
    <description>Peg+ Vitamin D+ Ribavirine</description>
    <arm_group_label>Peg+ Vitamin D+ Ribavirine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg+ Ribavirine</intervention_name>
    <description>Peg+ Ribavirine</description>
    <arm_group_label>Peg+ Ribavirine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years of age,

          -  Chronic genotype 2,3 HCV infection, Traetment Naive

          -  Negative sero for HBV, HDV and HIV viral infections

          -  Absolute neutrophil count of &gt;1500 per cubic millimeter, a platelet count of &gt;90,000
             per cubic millimeter

          -  Normal hemoglobin level

        Exclusion Criteria:

          -  Decompensated liver disease (cirrhosis with CP score &gt;9)

          -  Another cause of clinically significant liver disease

          -  Hepato cellular carcinoma

          -  Psychiatric Disorder

          -  Chronic heart failure

          -  Pregnant women

          -  Uncontrolled diabetes with retinopathy

          -  Arythmia

          -  Active CAD

          -  Positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Assy Nimer, MD</last_name>
    <phone>+97246828445</phone>
    <email>assy.n@ziv.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liver clinic</name>
      <address>
        <city>Hedera</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saif Abu Much, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziv medical center liver unit</name>
      <address>
        <city>Safed, Israel</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nimer Assy, MD</last_name>
      <phone>+972-46828445</phone>
      <email>assy.n@ziv.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Liver Clinic</name_title>
    <organization>Ziv medical center</organization>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Genotype2,3</keyword>
  <keyword>SVR</keyword>
  <keyword>Naive</keyword>
  <keyword>RVR rate</keyword>
  <keyword>EVR rate</keyword>
  <keyword>SVR rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

